Glioblastoma — Phase 1 trials
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE1 / PHASE2RECRUITING
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Intra-arterial Cetuximab · Intra-arterial Mannitol — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Pembrolizumab · Stereotactic Radiation Therapy · Surgical Resection — 1 site
- TRIALPHASE1RECRUITING
Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells
NK cells — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
IA Carboplatin + Radiotherapy in Relapsing GBM
IA Carbo+ Radiation — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
EBNK-001 + IL-15 + Pembrolizumab — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
LAM561 — 3 sites
- TRIALPHASE1 / PHASE2RECRUITING
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
pH Measurement of in vivo tissue — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor
Gallium maltolate
- TRIALPHASE1RECRUITING
GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
15.GPC3-CAR T cells — 1 site
- TRIALPHASE1RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Dual-target CAR-NK cells · Cyclophosphamide · Intracranial catheter/reservoir for locoregional delivery — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Near-Infrared Fluorescence Imaging · Panitumumab · Panitumumab-IRDye800 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
TGX-007 · Valaciclovir — 2 sites
- TRIALPHASE1RECRUITING
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
G207 — 3 sites
- TRIALPHASE1RECRUITING
A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV · Neurosurgery and intracavitary injection nivolumab and ipililumab · Adjuvant nivolumab IV + nivolumab and ipililumab intracavitary — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
ADV/HSV-tk (gene therapy) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
LMP744 · Conventional Surgery or Biopsy — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
CM93
- TRIALPHASE1NOT_YET_RECRUITING
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
CBX-663 — 1 site
- TRIALPHASE1RECRUITING
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
D2C7-IT · 2141 V11 — 1 site
- TRIALPHASE1ENROLLING_BY_INVITATION
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
Nivolumab · Azacitidine (AZA) · lumbar puncture — 1 site
- TRIALPHASE1NOT_YET_RECRUITING
FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma
Biospecimen Collection · Computed Tomography · Dexamethasone — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
P134 cell injection — 1 site
- TRIALPHASE1RECRUITING
Anti-GD2 ADC M3554 in Advanced Solid Tumors
M3554 — 11 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
ADI-PEG 20 (Arginine deiminase pegylated) · Temozolomide (TMZ) · Standard of Care Radiation Therapy (RT) — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Rhenium Liposome Treatment — 3 sites
- TRIALPHASE1RECRUITING
Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors
CS231295 — 2 sites
- TRIALPHASE1RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Eflornithine (Dose Level 1) · Eflornithine (Dose Level 2) · Eflornithine (Dose Level -1) — 8 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Debio 0123 · Temozolomide · Radiotherapy — 16 sites
- TRIALPHASE1 / PHASE2RECRUITING
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
D2C7-IT · 2141-V11 — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
DB107-RRV · DB107-FC · Radiation Therapy (RT) — 5 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.